T1	Participants 129 188	advanced gastric or gastroesophageal cancer adenocarcinoma:
T2	Participants 221 290	For patients with advanced gastric or gastroesophageal cancer (AGGEC)
T3	Participants 512 592	In a multinational trial (V325), 445 patients were randomly assigned and treated
